Showing 3751-3760 of 5910 results for "".
- PolyActiva Appoints Jerry St. Peter as CEO; Secures Financing to Advance Prezia Technology Platformhttps://modernod.com/news/polyactiva-appoints-jerry-st-peter-as-ceo-secures-financing-to-advance-prezia-technology-platform/2482854/PolyActiva announced two milestones in its next phase of growth: the appointment of biopharmaceutical executive Jerry St. Peter as CEO and board director, and the successful close of a $25M Series C funding round led by an Australian Sovereign Wealth Fund
- Johnson & Johnson Launches Tecnis Odyssey IOL in Europe, the Middle East, and Canadahttps://modernod.com/news/johnson-johnson-launches-tecnis-odyssey-iol-in-europe-the-middle-east-and-canada/2482853/Johnson & Johnson announced that it is expanding its portfolio of presbyopia-correcting intraocular lenses (PC-IOL) with the roll-out of Tecnis Odyssey IOL in Europe, the Middle East, and Canada. According to J&J, the new full visual range IOL offers high-quality and c
- Heidelberg Engineering Launches ZinserLab Innovation Hub to Accelerate Imaging Innovation in Eye Carehttps://modernod.com/news/heidelberg-engineering-launches-zinserlab-innovation-hub-to-accelerate-imaging-innovation-in-eye-care/2482848/Heidelberg Engineering announced the launch of the ZinserLab, an innovation hub that aims to accelerate the development of imaging technologies with clinical value for eye care. The hub is named in honor of Dr. Gerhard Zinser, the
- Ashvattha Therapeutics to Present Phase 2 DME and Wet AMD Datahttps://modernod.com/news/ashvattha-therapeutics-to-present-phase-2-dme-and-wet-amd-data/2482846/Ashvattha Therapeutics announced it will present new data focusing on previously reported phase 2 clinical data on migaldendranib, its investigational subcutaneous therapy for diabetic macular edema (DME) and wet age-related macular degeneration (AMD), which could offer a
- SpliceBio Secures $135M Series B to Advance Gene Therapy for Stargardt Diseasehttps://modernod.com/news/splicebio-secures-135m-series-b-to-advance-gene-therapy-for-stargardt-disease/2482845/SpliceBio announced the closing of a $135 million Series B financing round to support the clinical advancement of SpliceBio’s lead gene therapy candidate, SB-007, for Stargardt disease. There are currently no approved treatments for the disease, which is
- Gore Launches 0.5 mL Silicone-Free Gore Improject Plunger for Ophthalmic Pre-Filled Syringeshttps://modernod.com/news/gore-launches-05-ml-silicone-free-gore-improject-plunger-for-ophthalmic-pre-filled-syringes/2482843/W. L. Gore & Associates announced the commercial launch of the 0.5 mL silicone-free Gore Improject syringe plunger. The new offering, made within the company's PharmBIO business, is designed for prefilled syringes used in various applications, including ophthalmic intr
- Harrow Acquires US Commercial Rights to Byqlovi for Postoperative Inflammation and Painhttps://modernod.com/news/harrow-acquires-us-commercial-rights-to-byqlovi-for-postoperative-inflammation-and-pain/2482841/Harrow and Taiwan-based Formosa Pharmaceuticals announced a licensing agreement in which Harrow has acquired the exclusive US commercial rights for Byqlovi (clobetasol propionate ophthalmic suspension) 0.05%. Financial terms of the deal were not d
- EyeCare4Kids Names Maggie Cline as New CEOhttps://modernod.com/news/eyecare4kids-names-maggie-cline-as-new-ceo/2482838/The non-profit EyeCare4Kids announced the promotion of Maggie Cline, MPH, to Chief Executive Officer (CEO). Ms. Cline joined EyeCare4Kids in 2022 and served as Executive Director Utah, where she oversaw the delivery of more than 50,000 vision services annually at school clinics, community centers
- Bausch + Lomb Launches Blink Nourish and Blink Boost Lubricating Eye Drops in the UShttps://modernod.com/news/bausch-lomb-launches-blink-nourish-and-blink-boost-lubricating-eye-drops-in-the-us/2482834/Bausch + Lomb announced the US launch of Blink Nourish and Blink Boost lubricating eye drops. According to B+L, both products are preservative-free, contact-lens friendly and uniquely formulated to provide hydration and comfort for dry e
- iVeena Submits IND Application to the FDA for Phase 2 Clinical Trial for Pediatric Myopiahttps://modernod.com/news/iveena-submits-ind-application-to-the-fda-for-phase-2-clinical-trial-for-pediatric-myopia/2482830/iVeena Delivery Systems announced the submission of an investigational new drug (IND) application to the FDA for IVMED-85 for the treatment of pediatric myopia. IVMED-85 is a new chemical entity (NCE), p